|Description||Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.|
|Synonyms||GS-9820; GS9820; GS 9820; CAL-120; CAL 120; CAL120; Acalisib; UNII-OVW60IDW1D.|
|Current Developer||Gilead Sciences|
AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.
PI 828 is a cell permeable 4′-amino derivative which inhibits the p110α, p110β, p110δ, and p110γ subunits of PI 3-kinase. PI-828 is a potent inhibitor of phosph...
AS 252424 bispotassium salt is the potassium salt form of AS 252424, which is a potent and selective PI3K p110γ inhibitor.
740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...
XL PI3K/mTOR inhibitor
An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...